Insight Molecular Diagnostics
IMDX
27 hedge funds and large institutions have $54.1M invested in Insight Molecular Diagnostics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
11% more capital invested
Capital invested by funds: $48.9M → $54.1M (+$5.14M)
3.51% more ownership
Funds ownership: 53.38% → 56.89% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 30 → 27 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$2.62M |
| 2 |
Millennium Management
New York
|
+$157K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$115K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$80.2K |
| 5 |
State Street
Boston,
Massachusetts
|
+$62.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$99.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$53.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$35.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $10 | – | – | – |
|
|
GRP
27
Global Retirement Partners
San Rafael,
California
| $3 | – | – | – |
|
|
DC
28
Defender Capital
Charlotte,
North Carolina
| – | -$99.4K | -32,928 | Closed |
|
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$35.6K | -11,795 | Closed |
|
30
Raymond James Financial
St Petersburg,
Florida
| – | -$3.59K | -1,189 | Closed |
|
31
Fidelity Investments
Boston,
Massachusetts
| – | -$15 | -5 | Closed |
|
IMDX Hedge Fund Activity: Q3 2025 in Review
27 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2025, worth a combined $54.1M — up 11% from $48.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IMDX and 1 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Pura Vida Investments, adding an estimated $2.62M. The largest seller was Defender Capital, exiting entirely with an estimated $99.4K sold.
- 27 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2025, down from 30 in Q2 2025.
- Funds reported $54.1M of Insight Molecular Diagnostics stock for Q3 2025, up 11% quarter-over-quarter.
- 1 fund opened new Insight Molecular Diagnostics positions in Q3 2025 and 4 closed out, a net change of -3 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2025 was Pura Vida Investments, an estimated $2.62M added.
- The largest Insight Molecular Diagnostics seller in Q3 2025 was Defender Capital, an estimated $99.4K sold.
Based on aggregated 13F filings for Q3 2025.